BioPharma Dive - Latest News

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is departing after 14 years.

Mar 12, 2025 - 17:21
 0
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is departing after 14 years.

Read More

Tags:

Previous Article

Roche broadens obesity drug plans with $1.7B Zealand deal

Next Article

LeSportsac drops four new lines in Roberto Cavalli collaboration

Related Posts

Mirum drug for rare genetic disease gains FDA approval

Mirum drug for rare genetic disease gains FDA approval

Feb 24, 2025  0

Summit partners with Pfizer to study bispecific, ADC combinations

Summit partners with Pfizer to study bispecific, ADC co...

Feb 24, 2025  0

Bristol Myers, bracing for key patent losses, deepens cost-cutting plan

Bristol Myers, bracing for key patent losses, deepens c...

Feb 9, 2025  0